Figure 3

Kaplan-Meier estimates of time to second progression, measured from the date of second-line therapy initiation to that of tumor progression or death in the absence of progression in patients whose initial treatment was docetaxel plus trastuzumab (solid line) or vinorelbine plus trastuzumab (dashed line). The analysis is based on 69 and 49 events occurring in 80 and 57 patients who had initially received trastuzumab with docetaxel or vinorelbine, respectively.